Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY 4.0Molecular Therapy

A complement C5-targeted GalNAc-conjugated siRNA with sustained efficacy in a non-human primate model of IgA nephropathy

4 affiliations
  1. 1CSPC Pharmaceutical Group Limited, Shijiazhuang 050035, P.R. China
  2. 2School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
  3. 3Department of Emergency and Critical Care Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu 215000, China
  4. 4Shanghai Pudong Hospital, State Key Laboratory of Genetics and Development of Complex Phenotypes, Department of Biochemistry and Biophysics, School of Life Sciences, Fudan University, Shanghai 200438, P.R. China

Abstract

Immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis worldwide, is pathologically characterized by excessive complement activation. While multiple therapeutic approaches have been explored for IgAN, efficacious complement-targeted therapies for clinical use are still scarce. In the present work, we describe the preclinical profile of a N-acetylgalactosamine-conjugated small interfering RNA (GalNAc-siRNA) targeting complement component 5 (C5) for the treatment of IgAN. This C5-siRNA exhibited picomolar inhibitory activity in vitro, with an IC50 value of 0.013 nM. In cynomolgus non-human primates, a single subcutaneous injection yielded sustained C5 suppression of over 80% for 2 months and more than 50% for up to 4 months, a duration significantly longer than is possible with existing complement inhibitors. Furthermore, we conducted a head-to-head efficacy comparison with Nefecon, an approved therapeutic agent for IgAN, in a cynomolgus monkey IgAN model. While both treatments showed comparable improvements in key renal function parameters, the C5-siRNA achieved superior pathological remission and near-complete blockade of glomerular C5 deposition and membrane attack complex formation. Collectively, this study provides a strong rationale for the clinical development of C5-siRNA as an excellent therapy for IgAN, either as a standalone monotherapy or in combination with agents targeting upstream pathogenic pathways.

Related

  1. A Deformulating Multi-Attribute SEC Method for Simultaneous Quantification of Total RNA, Conjugated Antibody, and Free Antibody in Targeted Lipid Nanoparticles
    J. R. Filteau, A. P. Manuilov, G. M. Rubin +6
    bioRxivPreprintAll rights reservedFull textBiophysicsbioRxiv
  2. Engineered Brain‐Targeted Exosomes Delivering FGF1 for Sustained Glycemic Regulation and Multitarget Neurovascular Protection in Diabetic Stroke
    Bixin Shen, Chengxiang Zhang, Junhui Wang +5
    Advanced SciencePeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationPMC
  3. A Multidimensional Engineering Strategy Reprograms Microglia via Targeted and Sustained‐Release Extracellular Vesicles for Spinal Cord Injury Repair
    Wu Xiong, Minhao Liu, Mingming Zheng +15
    Advanced SciencePeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationPMC
  4. Endogenous Retrovirus-Targeted Immunotherapy for Non-Small Cell Lung Cancer Supported by Cellular HERV-K Expression, Dependency and Efficacy of ERV Therapy in a Murine Model
    Maria Perez-Penco, Tara Elizabeth Scott, Emilie Sofie Engdal +8
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General biochemistryCrossref
  5. Influence of antibody-antigen interaction on fluorescence of Rhodamine 6G conjugated to the antibodies measured in human serum
    D. Thiyagaraj, A. Del Re, Q. D. Pham +3
    bioRxivPreprintCC BY-NCFull textBiophysicsbioRxiv
BibTeX
@article{zhang2026complement,
  title = {{A complement C5-targeted GalNAc-conjugated siRNA with sustained efficacy in a non-human primate model of IgA nephropathy}},
  author = {Xueyan Zhang and Xue Zhang and Qiuyu Yang and Bin Kang and Mo Dan and Chunlei Li and Yan Chen and Jianhua Gan and Xiaoye Su},
  journal = {Molecular Therapy},
  year = {2026},
  month = aug,
  doi = {10.1016/j.ymthe.2026.08.022},
  url = {https://doi.org/10.1016/j.ymthe.2026.08.022},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - A complement C5-targeted GalNAc-conjugated siRNA with sustained efficacy in a non-human primate model of IgA nephropathy
AU  - Xueyan Zhang
AU  - Xue Zhang
AU  - Qiuyu Yang
AU  - Bin Kang
AU  - Mo Dan
AU  - Chunlei Li
AU  - Yan Chen
AU  - Jianhua Gan
AU  - Xiaoye Su
PY  - 2026
DA  - 2026/08/13
JO  - Molecular Therapy
DO  - 10.1016/j.ymthe.2026.08.022
UR  - https://doi.org/10.1016/j.ymthe.2026.08.022
AB  - Immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis worldwide, is pathologically characterized by excessive complement activation. While multiple therapeutic approaches have been explored for IgAN, efficacious complement-targeted therapies for clinical use are still scarce. In the present work, we describe the preclinical profile of a N-acetylgalactosamine-conjugated small interfering RNA (GalNAc-siRNA) targeting complement component 5 (C5) for the treatment of IgAN. This C5-siRNA exhibited picomolar inhibitory activity in vitro, with an IC50 value of 0.013 nM. In cynomolgus non-human primates, a single subcutaneous injection yielded sustained C5 suppression of over 80% for 2 months and more than 50% for up to 4 months, a duration significantly longer than is possible with existing complement inhibitors. Furthermore, we conducted a head-to-head efficacy comparison with Nefecon, an approved therapeutic agent for IgAN, in a cynomolgus monkey IgAN model. While both treatments showed comparable improvements in key renal function parameters, the C5-siRNA achieved superior pathological remission and near-complete blockade of glomerular C5 deposition and membrane attack complex formation. Collectively, this study provides a strong rationale for the clinical development of C5-siRNA as an excellent therapy for IgAN, either as a standalone monotherapy or in combination with agents targeting upstream pathogenic pathways.
SN  - 1525-0016
SN  - 1525-0024
ER  -